期刊文献+

Long-term follow-up of HER2 overexpression in patients with rectal cancer after preoperative radiotherapy:A prospective cohort study

下载PDF
导出
摘要 BACKGROUND The role of HER2 overexpression in rectal cancer is controversial.AIM To assess the role of HER2 overexpression in the long-term prognosis of rectal cancer.METHODS Data from patients with locally advanced rectal cancer who underwent total mesorectal excision after short-course radiotherapy at Beijing Cancer Hospital between May 2002 and October 2005 were collected.A total of 151 tissue samples of rectal cancer were obtained using rigid proctoscopy before neoadjuvant radiotherapy,followed by immunohistochemistry and fluorescence in situ hybridisation to determine the patients’HER2 expression status.Univariate and multivariate analyses of the associations between the clinicopathological factors and HER2 status were performed.Survival was estimated and compared using the Kaplan-Meier method based on HER2 expression status,and the differences between groups were verified using the log-rank test.RESULTS A total of 151 patients were enrolled in this study.A total of 27(17.9%)patients were ultimately confirmed to be HER2-positive.The follow-up duration ranged from 9 mo to 210 mo,with a median of 134 mo.Distant metastasis and local recurrence occurred in 60(39.7%)and 24(15.9%)patients,respectively.HER2 positivity was significantly associated with the pre-treatment lymph node stage(pre-N)(P=0.040),while there were no differences between HER2 status and age,sex,preoperative CEA levels(pre-CEA),T stage,and lympho-vascular invasion.In terms of prognosis,HER2 overexpression was correlated with distant meta stasis(P=0.002)rather than local recurrence(P>0.05).The multivariate analysis demonstrated that elevated pre-CEA[P=0.002,odds ratio(OR)=3.277,97.5%confidence interval(CI):1.543-7.163],post N(+)(P=0.022,OR=2.437,97.5%CI:1.143-5.308)and HER2(+)(P=0.003,OR=4.222,97.5%CI:1.667-11.409)were risk factors for distant metastasis.The survival analysis showed that there were significant differences between rectal cancer patients in terms of disease-free survival(DFS)[hazard ratio:1.69(95%CI:0.91-3.14);P=0.048]and overall survival(OS)[1.95(1.05-3.63);P=0.0077].CONCLUSION HER2 overexpression is a potential biomarker for predicting lymph node metastasis and distant metastasis,which are associated with worse long-term DFS and OS in rectal cancer patients with locally advanced disease.
出处 《World Journal of Gastrointestinal Oncology》 SCIE 2022年第10期2048-2060,共13页 世界胃肠肿瘤学杂志(英文版)(电子版)
基金 Supported by Beijing Municipal Administration of Hospitals Incubating Program,No.PZ2020027 Beijing Talent Incubating Funding,No.2019-4.
  • 相关文献

参考文献1

二级参考文献30

  • 1Akiyama, T., Sudo, C., Ogawara, H., et al., 1986. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science, 232(4758): 1644-1646. [doi:10.1126/science.3012781].
  • 2Baiocchi, G., Lopes, A., Coudry, R.A., et al., 2009. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int. J. Colorectal Dis., 24(9): 1059-1068. [doi: 10. 1007/s00384-009-0702-6].
  • 3Bang, Y.J., van Cutsem, E., Feyereislova, A., et al., 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial. Lancet, 376(9742):687-697. [doi:10.1016/S0140- 6736(10)61121-X].
  • 4Blok, E.J., Kuppen, P.J.K., van Leeuwen, J.E.M., et al., 2013. Cytoplasmic overexpression of HER2: a key factor in colorectal cancer, Clin. Med. Insights Oncol., 7:41-51. [doi: 10.4137/CMO.S 10811].
  • 5Chen, J., Li, Q., Wang, C., et al., 2010. Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases. Ann. Surg. Oncol., 17(6): 1555-1563. [doi: 10.1245/s 10434-009-0897-3].
  • 6Conradi, L.C., Styczen, H., Sprenger, T., et al., 2013. Frequency of HER-2 positivity in rectal cancer and prognosis. Am. J. Surg. Pathol., 37(4):522-531. [doi:10. 1097/PAS.0b013e318272ff4d].
  • 7Ferlay, J., Shin, H.R., Bray, F., et al., 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 127(12):2893-2917. [doi:10.1002/ijc. 25516].
  • 8Gravalos, C., Jimeno, A., 2008. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol., 19(9): 1523-1529. [doi: 10.1093/annonc/mdn 169].
  • 9Higgins, J.P., Thompson, S.G., Deeks, J.J., et al., 2003. Measuring inconsistency in meta-analyses. BMJ, 327(7414):557-560. [doi: 10.1136/bmj.327.7414.557].
  • 10Jesus, E.C., Matos, D., Artigiani, R., et al., 2005. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. Acta Cirurg. Bras., 20(6):422-427. [doi: 10.1590/S0102-86502 005000600005].

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部